Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Nov
13
Today In Oncology
Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer
FDA Approves Durvalumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer
FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC
American Cancer Society Updates Prostate Cancer Screening Guideline
Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo